Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
about
The biological effects and clinical implications of BRCA mutations: where do we go from here?Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease PreventionCiliogenesis and the DNA damage response: a stressful relationshipManaging breast cancer in younger women: challenges and solutionsEverolimus in the Treatment of Metastatic Breast CancerPARP inhibitors in the management of breast cancer: current data and future prospectsNovel therapeutic strategies for patients with triple-negative breast cancerThe genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevanceIdentification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancerOpportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyInherited Mutations in Women With Ovarian CarcinomaPhase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patientsCase-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Counselling framework for moderate-penetrance cancer-susceptibility mutations.Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkBreast Cancer Update 2014 - Focus on the Patient and the Tumour.Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an exampleThe prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancerPrevalence of PALB2 mutations in Australian familial breast cancer cases and controlsDNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer PatientsMultigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic featuresA comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscapeClinical implications of molecular heterogeneity in triple negative breast cancer.Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2.A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.SEOM clinical guidelines in Hereditary Breast and ovarian cancer.Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohortNovel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast CancerBRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
P2860
Q26741851-FBAB0F53-CA61-4204-B2FF-5969740FFE02Q26744525-211DFDC6-F272-407D-85DA-DAA6D941FC4EQ26747601-4D6A32CE-7787-4162-81E9-C3B48BF986E9Q26771184-24CC3CA5-DC20-4984-BD26-BDA3D9921B20Q26784920-26C87412-60CC-415C-BE11-BBB2F2D6E199Q26798352-FFD6ACBC-FDB0-44AC-A2C5-A15CF5188B8AQ28067436-237F1F24-719E-451A-B1EA-753E959B0C05Q28074414-E968173A-7EDC-4BC3-A62F-7CF4AE0DE04DQ28271817-D6090D56-852F-4601-A051-16D2D26FC1B4Q29248325-42AB1F39-5D71-4457-94B9-B83AFF92BAC7Q30353433-8746A79A-C08D-4CA4-8388-1A7232947E28Q33440778-2DD8F455-28B8-4642-A723-E7C7DD9CF898Q33589487-861D328F-3B6E-4D9F-B190-5BB9FB13CCD9Q33618262-F7DC87B6-F145-44C1-907C-376558D150FCQ33677756-EF148ECF-6666-4CE9-9C25-50D5086674F4Q33769821-94989067-062B-45AA-8A67-95DBD0FD8BB9Q33784408-F066465E-2A3E-4373-9F3B-A3206DD24159Q33887682-6317A9E8-FFE5-444B-8188-1523689790A7Q33911135-9FE0B381-94E9-47FE-8841-A7F7F7CE4E85Q35054455-2B37EF2C-C2DF-48C5-A117-D836E3FA0AE1Q35180940-612AE1AD-44B8-4827-9288-33E1109BC43DQ35631708-0A6C9A1F-DD5E-4EE2-B11D-F1F55B8B866CQ35940364-630195C4-6294-4CB2-AA7F-79A609FB3EB8Q35964605-EA7AF4BB-C182-41E8-8DBC-3EB9A6B67AA3Q35993095-530B8881-836C-4506-B653-29671B3D21C0Q36039509-0DCC9D17-49B5-4E03-8E0C-EB4A36F4CC0DQ36098650-3CDD31E2-B834-4857-BE34-D91BA5BA6AE6Q36110709-05446EEB-24C0-48DF-B675-B60E989C581CQ36172054-186C2BBA-8390-4FB1-BC8C-CEFC8D1A173EQ36239238-B6F8D3F8-053A-435C-A599-C80E2225C86FQ36271396-923913D4-88CE-4FDF-A824-3E218DC438CEQ36274770-2CA10434-79B2-456E-9052-8A862BA7BCBAQ36338690-710A6FEF-6768-487B-BEE2-7ED0BAB52977Q36365067-9282818C-88CA-40C6-84CC-9E7AE5880513Q36400244-9D26B0CD-ED41-4B5B-84D1-6690193222ECQ36808649-7C566EB9-AFC8-4E6E-B74D-2C732DA0B183Q36886874-9F9D7C35-D8E8-461C-AF3C-80E762D8ED1AQ36890898-2BBCD480-60FC-4382-8E5F-F25C5BB55185Q36902674-44977C12-5388-4B8A-896A-0629DE126118Q36915151-31C3B5F2-343E-4C10-B745-1FC3950F7702
P2860
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Inherited mutations in 17 brea ...... mily history of breast cancer.
@ast
Inherited mutations in 17 brea ...... mily history of breast cancer.
@en
Inherited mutations in 17 brea ...... mily history of breast cancer.
@nl
type
label
Inherited mutations in 17 brea ...... mily history of breast cancer.
@ast
Inherited mutations in 17 brea ...... mily history of breast cancer.
@en
Inherited mutations in 17 brea ...... mily history of breast cancer.
@nl
prefLabel
Inherited mutations in 17 brea ...... mily history of breast cancer.
@ast
Inherited mutations in 17 brea ...... mily history of breast cancer.
@en
Inherited mutations in 17 brea ...... mily history of breast cancer.
@nl
P2093
P2860
P50
P356
P1476
Inherited mutations in 17 brea ...... mily history of breast cancer.
@en
P2093
Andrew K Godwin
Athanassios Vratimos
Brigitte Rack
Charles L Shapiro
Curtis Olswold
Dennis J Slamon
Emily Hallberg
Jaime I Davila
Jennifer Klemp
Judy Garber
P2860
P304
P356
10.1200/JCO.2014.57.1414
P407
P50
P577
2014-12-01T00:00:00Z